Colorectal
MS9140001_0002 (PROCEADE-CRC-03)
A randomized, open-label, 3-arm Phase III study of precemtabart tocentecan as single agent or in combination with bevacizumab compared to trifluridine/tipiracil plus bevacizumab in participants with previously treated metastatic colorectal cancer (PROCEADE-CRC-03).
Trial overview
Clinical Area
Medical Oncology
Disease
Colorectal
Disease site
Gastrointestinal (GI)
Study Phase
III
Trial Identifiers
Registration number: NCT07549412
Principal Investigator(s)
Madhawa De Silva
Medical Oncologist
··
··